BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Memento EPFL//
BEGIN:VEVENT
SUMMARY:Personalized Assessment of CFTR Allosteric Modulators in Cystic Fi
 brosis Patients With Rectal Derived Organoids
DTSTART:20231123T170000
DTEND:20231123T180000
DTSTAMP:20260430T222459Z
UID:2081bfa925ef52af77edd3b049e600b60dbcb78b23e4e2b3e5043449
CATEGORIES:Conferences - Seminars
DESCRIPTION:Nathalie Brandenberg\, Ph.D.\, CEO\, Doppl SA & co-CEO\, SUN b
 ioscience\, Lausanne (CH)\nBIOENGINEERING SEMINAR\n \nAbstract:\nCystic f
 ibrosis (CF) is a genetic disease caused by a bi-allelic mutation of the c
 ystic fibrosis transmembrane conductance regulator (CFTR) gene. When the d
 iagnosis cannot be confirmed by a positive sweat test or/and the identific
 ation of two CF-causing variants\, international guidelines recommend the 
 use of CFTR functional assavs. These tests assess whether CFTR activity is
  normal or diminished/absent through measurement of CFTR-mediated chloride
  secretion/absorption.\n\nBio:\nPositions:\nJuly 2022 - Present    Foun
 der\, CEO and Board Member\, Doppl SA\, Lausanne (CH)\nJan 2016 - Present
     Founder\, co-CEO and Board Member\, SUN bioscience\, Lausanne (CH)
 \n\nEducation:\nAug. 2021-Dec. 2022    Executive MBA\, Business Admini
 stration and Management\, Healthcare Focus\, University of Lausanne (CH)\n
 2012-2016    Ph.D.\, Lutolf Lab\, EPFL\, Lausanne (CH)\n2010-2011   
  M.Sc. project\, The University of Tokyo\, Tokyo (JP)\n2006-2011    B.S
 c. in Life Science & Technology\, M.Sc. in Bioengineering\, EPFL\, Lausann
 e (CH)
LOCATION:AAC 1 08 https://plan.epfl.ch/?room==AAC%201%2008
STATUS:CONFIRMED
END:VEVENT
END:VCALENDAR